Logo

Invitrogen Chief Lyle Turner to Step Down Jan. 1; CEO, Chair Posts to Split

Dec 05, 2002

NEW YORK, Dec. 5 - Lyle Turner, the gregarious founder, CEO, and chairman of Invitrogen, will step down at the end of the year, the company said today.

 

James Glynn, Invitrogen's executive vice president and former CFO, has been named president and COO. When Turner leaves Jan. 1, Glynn will assume the role of interim CEO until a permanent chief is hired. Bradley Lorimier, a current board member, will become chairman.

 

Invitrogen said it hopes to have a new CEO in place before the end of June, though the company said it has no specific timeline.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.